Table 1. Clinical data of patients whose blood samples were included in the study.

Patient ID	Age	Sex	Disease	Immune suppression	Fever	Other symptoms	Vascular event	Tick bite	Infectious material	Cell line supporting growth of Neoehrlichia	First positive culture	Infected CEC detected	Ref.
SE15	57	F	Multiple sclerosis	Rituximab	1.5 months	Swollen foot, localized myalgia (trapezius muscle), bilateral pain lower legs upon exertion	Thrombo-phlebitis	Yes	Whole blood and plasma/buffy coat	IRE/CTVM20 ISE6	15 weeks	NA	[43]
SE17	58	M	Follicular lymphoma	Rituximab Chemotherapy	2 months	Myalgia upper and lower extremities, arthralgia both ankles	Repeated thrombo-phlebitis	Yes	Plasma/buffy coat	IRE/CTVM20	17 weeks	NA	[11]
SE21	63	F	Primary hypogamma-globulinemia (IgG1)	Splenectomy	1–2 weeks	Pain, sore palpation right flank and lower abdominal quadrant	No	Yes	Whole blood and plasma/buffy coat	ISE6	12 weeks	NA	[11]
SE23	48	F	Multiple sclerosis	Rituximab	4 months	Localized myalgia (left upper arm, left lower leg), arthralgia right wrist, swollen ankles, cough	Repeated muscle vein thromboses	No	Whole blood and plasma/buffy coat	IRE/CTVM20	20 weeks	Yes	This study
SE24	54	M	Granulomatosis with polyangiitis	Rituximab Chemotherapy IL-1R inhibitor Corticosteroids	1.5 years	Severe fatigue, skin rash, general myalgia, cough	DVT lower extremity	Yes	Whole blood and plasma/buffy coat	IRE/CTVM20 ATCC PCS-110-010 ATCC PCS-100-022	Tick cells: 9 weeks Endothelial cells: 15 days	NA	This study
SE25	62	M	Multiple sclerosis	Rituximab	2 months	Cough	No	Yes	Plasma/buffy coat	IRE/CTVM20 ATCC PCS-110-010 ATCC PCS-100-022	Tick cells: 7 weeks Endothelial cells: 6 days	NA	This study
SE26	65	M	B-Chronic lymphocytic leukemia	Rituximab Chemotherapy	6 days	Localized myalgia (neck), headache, cough	DVT upper extremity	No	NA	NA*	NA*	Yes	This study

Note: F = female, M = male, NA = not assessed, NA* = not assessed because of insufficient material, CEC = circulating endothelial cells.